{"id":51129,"date":"2022-11-22T14:02:26","date_gmt":"2022-11-22T13:02:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/"},"modified":"2022-11-22T14:02:26","modified_gmt":"2022-11-22T13:02:26","slug":"ocuterra-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"OcuTerra to Participate in Upcoming Investor Conferences"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc.<\/a> (\u201cOcuTerra\u201d), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of \u201cwatch-and-wait\u201d does not prevent or control the progression of disease, today announced the company\u2019s participation in two upcoming investor conferences.\n<\/p>\n

<\/a><\/p>\n

\nOcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will give a fireside chat at BTIG\u2019s Ophthalmology Day on November 29.\n<\/p>\n

\nBTIG Ophthalmology Day
\n
<\/b>Session: Fireside Chat
\n
Date & Time: November 29, 2022, 11:30-11:55am ET\n<\/p>\n

\nMs. Brady will also participate in the ophthalmology panel at Cantor Fitzgerald\u2019s Medical and Aesthetic Dermatology & Ophthalmology Conference.\n<\/p>\n

\nCantor Medical and Aesthetic Dermatology & Ophthalmology Conference
\n
<\/b>Session: Ophthalmology Panel: Take a Look at What’s in Store for Wet AMD & Related Diabetic Eye Diseases
\n
Date & Time: December 8, 2022, 2:45-3:30pm ET\n<\/p>\n

\nAbout OTT166
\n
<\/b>OTT166 is an investigational, novel, patented, potent and selective small molecule RGD integrin inhibitor designed with purpose engineering to have an optimum balance of physiochemical properties to allow it to distribute to the retina in high concentrations after topical (eye drop) administration to the eye. In preclinical studies, OTT166 selectively inhibited key RGD integrin subtypes, including \u03b1v\u03b23, to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases. In early clinical trials in patients with diabetic retinal disease, OTT166 eye drops have demonstrated preliminary evidence of tolerability and biological activity.\n<\/p>\n

\nAbout OcuTerra Therapeutics
\n
<\/b>OcuTerra Therapeutics, Inc. is developing innovative drugs for ophthalmic diseases for which the current standard of care does not prevent or control the [early] progression of disease. Our initial therapeutic candidate, OTT166, administered as an eye drop containing a novel, potent and selective integrin-inhibitor, is in clinical development as an early, non-invasive intervention for diabetic retinopathy, a chronic, progressive disease that is one of the leading causes of vision loss globally. Our goal is to bring transformative treatments to patients and their clinicians who are currently consigned to watch and wait as disease progresses, ultimately requiring medically intensive and invasive therapy. www.ocuterratx.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMacDougall Advisors
\n
Carolyn Noyes
\n
cnoyes@macdougall.bio<\/a>
781-235-3060\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. (\u201cOcuTerra\u201d), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of \u201cwatch-and-wait\u201d does not prevent or control the progression of disease, today announced the company\u2019s participation in two upcoming investor conferences. OcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51129","6":"format-standard","7":"category-industry"},"yoast_head":"\nOcuTerra to Participate in Upcoming Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OcuTerra to Participate in Upcoming Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. (\u201cOcuTerra\u201d), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of \u201cwatch-and-wait\u201d does not prevent or control the progression of disease, today announced the company\u2019s participation in two upcoming investor conferences. OcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-22T13:02:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221122005173\/en\/1144591\/21\/OcuTerra_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"OcuTerra to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2022-11-22T13:02:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":365,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221122005173\\\/en\\\/1144591\\\/21\\\/OcuTerra_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"OcuTerra to Participate in Upcoming Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221122005173\\\/en\\\/1144591\\\/21\\\/OcuTerra_logo.jpg\",\"datePublished\":\"2022-11-22T13:02:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221122005173\\\/en\\\/1144591\\\/21\\\/OcuTerra_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221122005173\\\/en\\\/1144591\\\/21\\\/OcuTerra_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ocuterra-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OcuTerra to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OcuTerra to Participate in Upcoming Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"OcuTerra to Participate in Upcoming Investor Conferences - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–OcuTerra Therapeutics, Inc. (\u201cOcuTerra\u201d), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of \u201cwatch-and-wait\u201d does not prevent or control the progression of disease, today announced the company\u2019s participation in two upcoming investor conferences. OcuTerra CEO & President Kerrie Brady, BPharm, MS, MBA, will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-22T13:02:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221122005173\/en\/1144591\/21\/OcuTerra_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"OcuTerra to Participate in Upcoming Investor Conferences","datePublished":"2022-11-22T13:02:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/"},"wordCount":365,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221122005173\/en\/1144591\/21\/OcuTerra_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/","name":"OcuTerra to Participate in Upcoming Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221122005173\/en\/1144591\/21\/OcuTerra_logo.jpg","datePublished":"2022-11-22T13:02:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221122005173\/en\/1144591\/21\/OcuTerra_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221122005173\/en\/1144591\/21\/OcuTerra_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ocuterra-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"OcuTerra to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51129"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51129\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}